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Abstract
Background: The European Medicines Agency does not recommend the use of hydroxyethyl starch-based volume
replacement solutions in critically ill patients due to an increased risk of renal failure. However, this recommendation is
questionable for its perioperative use. Several recent randomised controlled studies do not indicate a risk for renal
failure—not even after high-risk surgery. Human albumin is used in our neurointensive care unit as a part of the “Lund
concept” of brain injury resuscitation, and albumin has been introduced in elective neurosurgery instead of starch. The
aim of our prospective unblinded observational cohort study was to compare the degree of dilutive coagulopathy
after albumin and starch intra-operative fluid therapy.
Methods: Thirty-nine patients undergoing elective brain tumour surgery with craniotomy received either 130/0.42
hydroxyethyl starch or 5 % albumin infusions. The first 18 patients received starch, whereas the rest received albumin.
Rotational thromboelastometry with ROTEM and platelet aggregometry with Multiplate were performed before
surgery, after the first and second consecutive colloid infusions (250/500 ml albumin or 500/1000 ml starch) and at the
end of surgery.
Results: Both intra- and inter-group comparisons showed more deranged ROTEM parameters after the higher doses of
starch. Multiplate detected changes only in the albumin group after 500-ml infusion. Blood los did not differ between
groups, nor did haemoglobin preoperatively or at end of surgery. Lower volumes of albumin were required to
maintain stable intra-operative haemodynamic parameters; 250/500 ml albumin corresponded to 500/1000 ml starch.
Conclusions: Hydroxyethyl starch affected coagulation at lower volumes, with a more prominent effect on clot
structure at the end of surgery, corroborating previous research. Only albumin decreased platelet aggregation, and 5 %
albumin had a more potential volume effect than 130/0.42 hydroxyethyl starch.
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Background
In brain tumour neurosurgery, intra- and post-operative
bleeding in brain tumour resection can be linked to the
vascularity of the tumours, tumour size and localization
(Goh et al. 1997). Most of the losses will be surgical, and
as the field is open, direct haemostasis with cautery or
topical coagulants is more relevant. Post-operative
hematomas are rare but may be more related to a
coagulopathy than a surgical bleed. During surgery,
different fluids are used to replace blood loss and
maintain arterial pressure, including crystalloids and
blood products, and during the last few decades,
synthetic colloids as well. However, all of these fluids
are associated with adverse effects, and an ideal fluid
for haemodynamic stabilisation and resuscitation has
yet to be found.
Hydroxyethyl starches (HESs) are synthetic colloids
with different molecular weights and substitutions that
are used for their plasma-expanding effects. In recent
years, several studies have highlighted the adverse effects
of this colloid, particularly the risk of acute renal failure
(Zarychanski et al. 2013), allergic skin manifestations
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and hypocoagulability following infusion. HES has been
shown to impair clot strength, platelet function and in-
crease fibrinolysis to an extent that cannot be explained
by haemodilution alone (Levi & Jonge 2007). HES infu-
sions decrease plasma levels of fibrinogen and several
coagulation factors, leading to weaker and smaller clots
(Fenger-Eriksen et al. 2009). It can also decrease cir-
culating levels of von Willebrand’s factor (F), thus
impairing platelet function (de Jonge et al. 2001).
In Europe, market authorisations for HES have been
suspended due to these findings (Agency EM. PRAC
recommends suspending marketing authorisations for
infusion solutions containing hydroxyethyl starch:
European Medicines Agency & [cited 2013 Jun 14]).
However, the clinical perioperative implications of
these findings are still uncertain for stable patients
undergoing elective surgery (Moral et al. 2013). Hu-
man albumin (HA) is an alternative fluid that has re-
cently been replacing HES in neurosurgery at Lund
University Hospital. Albumin is used by us in accord-
ance with the “Lund concept” of brain injury resusci-
tation (Grande 2011), and for us, it was natural to
replace HES with HA. However, in large meta-
analyses on the effectiveness of HA on patient mor-
tality and morbidity, no significant benefits have been
shown when comparing HA to synthetic colloids or
crystalloids (Perel et al. 2013; Roberts et al. 2011).
HA may have lesser impact on coagulation compared
to synthetic colloids (Niemi et al. 2006), which is a
desirable quality for perioperative use. The coagulopa-
thy caused by HA also seems to be easily reversed by
fibrinogen and FXIII concentrate (Winstedt et al.
2013), making it a potentially better fluid for patients
that might already suffer from a coagulopathy or risk
of developing one.
Routine clinical laboratory analyses of coagulation,
such as activated partial thromboplastin time (aPTT)
and prothrombin time (PT), are plasma-based and might
not correctly predict a clinical coagulopathy. Whole
blood viscoelastic methods, such as thromboelastometry
(e.g. ROTEM®) and whole blood-aggregometry (e.g. Mul-
tiplate®), have gained recognition as alternative methods.
Thromboelastometry is able to assess global haemostatic
functions, and platelet aggregometry assesses platelet
function in response to different reagents. These systems
have already been introduced clinically as point-of-care
methods for quickly determining bleeding risk and
helping to guide transfusions (Shore-Lesserson et al.
1999). They have also been used to study haemostasis
in different critical care situations, such as trauma
(Solomon et al. 2011) and sepsis (Brenner et al.
2012). ROTEM is known to detect colloid-induced
coagulopathy (Fenger-Eriksen et al. 2009), even at low
levels of dilution (Tynngård et al. 2014).
The purpose of this study was to compare the effects
on coagulation of 5 % HA and HES 130/0.42 in elective
brain tumour neurosurgical patients. Our aim was to in-
vestigate whether HA had a more favourable effect on
coagulation and platelet function, assessed by a visco-
elastic method and a platelet aggregometry method
(ROTEM and Multiplate, respectively). Our hypothesis
was that HA infusions would induce less hypocoagul-
ability than HES, as seen on ROTEM and Multiplate.
Methods
This study was performed as a prospective unblinded
observational cohort study with two colloid fluid regi-
mens. During 2013 and 2014, our fluid regimen for
haemodynamic stabilisation and initial blood-loss substi-
tution during elective brain tumour resection was chan-
ged from HES to 5 % HA. We had studied 18
consecutive patients with HES according to a protocol,
and our initial aim was to include more patients with
HES and the combined testing with ROTEM and Multi-
plate when the department replaced HES with HA.
We therefore decided to continue the protocol with
HA and compare its effects on ROTEM and Multiplate
with the data from the previous HES-patients. Accord-
ing to a power analysis from an in vitro study (Winstedt
et al. 2013), >15 patients in each group would give a
statistical power of 0.8 at a significance level of p < 0.05,
defined by detected differences in FIBTEM-MCF (see
below), as this is the best predictive ROTEM parameter
for dilutive coagulopathy, correlating with fibrinogen;
the first coagulation factor to reach critical low levels
during haemodilution (Winstedt et al. 2013).
General ethical approval was obtained from the Re-
gional Ethical Review Board (Lund, Protocol DNR 2012/
482) for monitoring neurosurgery patients with ROTEM
and Multiplate. Signed consent was received from all pa-
tients in the two test groups. All patients were over
18 years.
No patients with a known haemostatic disturbance,
anticoagulants, antiplatelet drugs (also including aspirin/
nonsteroidal anti-inflammatory drugs), abnormal pre-
operative coagulation analysis (aPTT/PT, platelet count),
known renal impairment or increased plasma-creatinine
level were included.
Anaesthesia was induced and maintained with propofol
(Diprivan®; AstraZeneca, Sweden) and remifentanil
(Ultiva®, GlaxoSmithKline, Sweden). Intubation was fa-
cilitated with rocuronium (Esmeron®; MSD, USA)
(0.5–0.8 mg/kg), and ventilation was maintained with
positive pressure ventilation in a circle system. Minute
ventilation was adjusted to maintain normocapnia (PaCO2
of 4.5–5.5 kPa).
After induction, a radial arterial catheter was inserted
for continuous measurement of blood pressure and for
Li et al. Perioperative Medicine  (2015) 4:9 Page 2 of 10
collection of blood samples, and a bladder catheter was
inserted for hourly measurement of diuresis.
All patients received thromboprophylaxis with mech-
anical calf compression (Kendall SCD™ Express Sleeves;
Covidien, USA) during surgery and postoperatively
for 24 h.
Normothermia during the surgery was maintained with
a Bair Hugger™ (3 M, St. Paul, USA) and oesophageal
temperature monitoring.
During this study, there was no intervention on our
part in the transfusion/infusion protocols. The crystal-
loid/colloid infusions and transfusion of blood compo-
nents were solely determined by the anaesthetist in
charge, based on a standard protocol from the anaesthe-
sia department (see below) and were not affected by the
study protocol or the ROTEM/Multiplate test results.
Standard Lund departmental protocol for perioperative
fluids during neurosurgery: After the induction of anaes-
thesia, a basal infusion of 1.5–2.0 ml/kg/h of saline
(NaCl 0.9 %; B. Braun Medical AB) was started. Initial
bleeding up to 200–300 ml was substituted with saline
(2–3 ml per 1 ml of bleeding). The HES group received
hydroxyethyl starch 130/0.42 in sodium chloride for
maintaining mean arterial pressure of >60–65 mm Hg,
systolic blood pressure >90 mmHg, pulse pressure vari-
ation (PPV) <12 mmHg and replacing bleeding of >200–
300 ml (see above) (1–2 ml HES per 1 ml of bleeding)
(HES; Venofundin® 60 mg/ml hydroxyethyl starch; MW
130 kDa; substitution 0.42; B. Braun Medical AG,
Germany). HES was thus also used to compensate for
the haemodynamic effects of anaesthesia. HES was re-
stricted to 1000 ml by the departmental protocol. The
HA group was given 5 % human albumin (Albumin;
CSL Behring, Germany) at 1–2 ml HA per 1 ml of
bleeding of >200–300 ml (see above). HA was also used
to compensate for the haemodynamic effects of anaes-
thesia as for HES. Albumin was restricted to 500 ml by
the departmental protocol.
According to departmental protocol, packed red blood
cells (PRBCs) are to be administered when the concen-
tration of haemoglobin reaches <95–100 gram/L, and
blood loss of more than 30 % of the calculated blood
volume is substituted with PRBCs, fresh-frozen plasma
(FFP) and platelet concentrates (PC).
Arterial blood was sampled from radial arterial cathe-
ters with a continuous sodium chloride flush system
with no heparin. The blood samples were collected in
2.7-ml citrated plastic vacuum tubes (3.2 % citrate; BD
Vacutainer systems, UK) for ROTEM and in 3.0-ml hiru-
din tubes (Dynabyte GmbH, Germany) for Multiplate
analysis. Blood sampling was performed before surgical
incision, after every colloid unit (i.e. after every 250 ml
HA or 500 ml HES infusion) and at the end of surgery;
altogether, three or four samples were collected per
patient. Blood loss during surgery was evaluated from
suction reservoir and swabs.
Arterial blood gases with haemoglobin, electrolyte, lac-
tate and glucose levels were analysed before the begin-
ning of surgery and during surgery every 1–2 h
(Radiometer ABL800 FLEX; Radiometer, Denmark).
Rotational thromboelastometry (ROTEM®; TEM Inno-
vations GmbH, Germany) measures the coagulation ini-
tiation, amplification and propagation kinetics of whole
blood. It uses a cup with a rotating pin, whose move-
ment is impeded as blood coagulates inside the cup. The
impedance reflects clot firmness and is plotted graphic-
ally against time. Analysis was carried out within 1 h
from blood sampling, during which time the samples
were kept at 37 °C. The following two assays were run
on each sample: EXTEM and FIBTEM. EXTEM mea-
sures coagulation activated by tissue factor (extrinsic
pathway), while the FIBTEM assay includes a platelet
inhibitor (cytochalasin D), thus measuring only fibrino-
gen activity. For EXTEM, the following parameters are
assessed for each analysis (normal range within brackets):
clotting time/CT (42–74 s), clot formation time/CFT
(46–148 s), alpha-angle/AA (63–81°) and maximum clot
firmness/MCF (63–81 mm). For FIBTEM, only MCF
(9–25 mm) was analysed. The normal ranges used were
established in a multi-centre study (Lang et al. 2005).
Multiple electrode aggregometry (Multiplate®; Roche
Diagnostics, Basel, Switzerland) measures platelet aggre-
gation in whole blood using electrical resistance between
two electrodes. As aggregation occurs, the increasing
impedance is plotted against time, and the area under
the curve (AUC) is a measure of platelet function. The
blood samples were kept at room temperature for 30–40
min before analysis, which was done at 37 °C. The fol-
lowing two test assays were performed for each sample:
platelet aggregation in response to adenosine diphos-
phate (ADP-test, AUC reference range 57–113) and
thrombin receptor-activating peptide (TRAP-test, AUC
reference range 84–128). For statistical analysis of the
data, both inter- and intra-group comparisons were
made. Normal distribution was not assumed (non-para-
metric data). Samples after first colloid infusion, after
second colloid infusion and at the end of surgery were
tested against the preoperative sample using the Wil-
coxon signed-rank test for paired samples. All ROTEM
and Multiplate values in one test group were also com-
pared to the corresponding values in the other test
group, using the Mann-Whitney U test for unpaired
samples. The level of significance was set to p < 0.017
after correction in accordance to Bonferroni, in order to
decrease the risk of type I errors due to multiple
comparisons. Results are presented as boxplots showing
median and interquartile range, with min-max whiskers
and + signs identifying mean values.
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Results
In total, 18 patients were included in the HES group and
21 patients in the HA group during a 5-month period.
The demographic, bleeding and transfusion/infusion
data for these patients are shown in Table 1. Six patients
received erythrocyte transfusions, one patient received
platelet transfusions and one patient received plasma
transfusions intra-operatively. There were no differences
in median haemoglobin concentration at the end of sur-
gery between the groups (Table 1). The decrease in
haemoglobin preoperative-postoperative was the same in
both groups.
Intra-group comparisons
Results from each sampling occasion were compared to
the preoperative results. In the HA group, the most sig-
nificant differences were detected after the second HA
infusion, as well as at the end of surgery (Tables 2 and 3
and Figs. 1, 2 and 3). After 250 ml HA, ROTEM only
showed a significant decrease in FIBTEM-MCF. After
500 ml HA, CFT, AA and EXTEM-MCF also differed as
compared to pre-surgery levels. At the end of surgery,
changes were detected in all ROTEM parameters except
for CT. Multiplate detected changes in the ADP param-
eter only after 500 ml HA. No other significant changes
could be shown in ADP or TRAP parameters. In the
HES group, significant differences could be detected
already after the first infusion (Table 2 and 3 and
Figs. 1, 2 and 3). After 500 ml HES, CFT was markedly
prolonged, as seen in Fig. 1. AA and EXTEM-MCF
both decreased (Fig. 2 (AA not shown)). Only after
1000 ml HES was CT prolonged (Tables 2 and 3 and
Fig. 1). Additionally, changes could be seen in the
CFT, AA and FIBTEM-MCF parameters after 1000 ml
HES, as well as after surgery (Tables 2 and 3). Multiplate
did not detect any significant differences within the HES
group (Fig. 3).
Inter-group comparisons
When comparing the two test groups against each other,
each parameter was compared to the corresponding
one in the other test group. Most of the changes oc-
curred after the first dose of colloid. Before the start
of surgery, only the CT parameter differed between
the groups (p = 0.0001), with a lower median CT in
the HES group. After the first colloid infusion, CT was
still significantly shorter in the HES group (p = 0.0014),
while CFT was longer (p = 0.0002). EXTEM-MCF
were lower (p = 0.001 and p = 0.0107, respectively) in
the HES group as compared to the HA group. After
the second dose of colloid infusion, no further
changes between the groups were detected. At the
end of surgery, the following two parameters differed
between the groups: CT (p = 0.0068) and FIBTEM-MCF
(p = 0.0117), which registered significantly lower values
in the HES test group. For Multiplate analysis, no
parameters were found to be different between the
two test groups.
There were no differences in the median arterial blood
gas parameters nor were there any differences in median
systolic, diastolic or mean arterial blood pressures, heart
rate or pulse pressure variation (only measured during
anaesthesia, with muscle relaxation and tidal volumes
of >10 ml/kg body weight and no arrhytmias) or in
intra- and post-operative median hourly diuresis between
the groups. Post-operatively, there was no increase in
plasma creatinine in either group (controlled 3–8 weeks
postoperatively).
Table 1 Demographic and bleeding data for patients receiving 5 % human albumin (HA) or hydroxyethyl starch 130/0.4 (HES)
during elective neurosurgery up to the end of surgery (eos)
HES (n = 18) HA (n = 21)
Gender (male/female) 10/8 7/14
Median age (min-max) 51(21–86) 54(20–73)
Blood loss (n) 100–499 ml (7) 100–499 ml (8)
500–999 ml (4) 500–999 ml (3)
1000–1999 ml (5) 1000–1999 ml (4)
≥2000 ml (1) ≥2000 ml (0)
Total colloid volume received (n) 500 ml (5) 250 ml (10)
1000 ml (13) 500 ml (11)
Total NaCl volume received (n) 2000 ml (15) 2000 ml (16)
2500 ml (2) 2500 ml (5)
3000 ml (2)
Median preoperative Hb (min-max) 128 g/L (99–148) 127 (97–144)
Median eos Hb (min-max) 116 g/L (96–122) 113 g/L (94–144)
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Discussion
Our results indicate that the two types of colloid infu-
sions induce coagulation defects in elective brain
tumour neurosurgical patients, most notably seen with
ROTEM parameters and after HES infusion. There are
dose-response effects with both HA and HES. At the
end of surgery, the HES group had more deranged
ROTEM values than the HA group, but had been in-
fused at a much higher volume ratio to assessed bleed-
ing. Multiplate showed only one significant intra-group
deterioration in the ADP parameter, detected after
500 ml HA, as compared to pre-surgery, and normalised
already at the end of surgery. No significant Multiplate
changes could be seen in the HES group.
Using viscoelastic or aggregometric techniques as
point-of-care methods for assessing perioperative bleed-
ing risks is a desirable option, since they provide faster
results than traditional laboratory-based tests. ROTEM
has already been used for this purpose and is able to de-
tect colloid-induced coagulopathies (Fenger-Eriksen et
al. 2009; Hartog et al. 2011); Multiplate has not been
studied as thoroughly in this aspect. One study used
Multiplate to detect impaired platelet function after
60 % colloid dilution in vitro (Kind et al. 2013), but the
clinical implications are uncertain as this represents an
extreme dilution seldom observed in clinical prac-
tice. In our study with colloid dilutions of 10–20 %,
Multiplate indicated a statistically significant lowered
ADP aggregation as compared to the preoperative
result only after 500 ml HA. However, at all sampling
points, median levels were within normal ranges for both
the ADP and TRAP reagents for both fluids. It is possible
that Multiplate is not sensitive enough to detect changes
in platelet function at low degrees of colloid dilution in
vivo. Multiplate is also affected by platelet count, espe-
cially at levels beneath 100 × 109/L (Hanke et al. 2010).
Only one of our patients had a low borderline platelet
count due to radiation therapy prior to surgery, and re-
ceived one unit of platelet transfusion at the beginning
of the surgery due to increased wound bleeding, and
additionally, 250 ml HA and three units of platelets
intra-operatively. This patient’s Multiplate values for
TRAP/ADP were 67/30 preoperatively, 59/18 after
250 ml HA and 128/34 at the end of surgery (after the
three units of platelet transfusions; patient’s data is not
included in the Multiplate data statistical evaluation).
This might indicate a colloid-induced effect on a low-
platelet function/count that is restored after additional
platelet transfusions.
In this study, blood samples were taken before the
start of surgery to determine a baseline value. Some of
these preoperative values fell outside of the normal
ROTEM ranges, possibly induced by the tumour itself or
stress due to anaesthesia (Hahnenkamp et al. 2002).
After the first volume of colloid infusion, there were sig-
nificant changes in several ROTEM parameters in the
Table 2 ROTEM and Multiplate parameters (median values, first and third quartiles within brackets) of patients receiving
hydroxyethyl starch 130/0.4 (HES) during brain tumour neurosurgery (n = 18), blood samples taken at different times during surgery
Pre-surgery After 500 ml HES After 1000 ml HES End of surgery
CT (s) 48 (45–53) 52 (47–57) 58 (54–63) 47 (44–56)
CFT (s) 96 (84–131) 137 (115–145) 144 (134–148) 130 (110–144)
AA (°) 72 (67–73) 64 (62–65) 63 (61–65) 65 (62–68)
MCF (mm) 59 (57–63) 55 (52–58) 57 (50–58) 56 (51–62)
FIBTEM-MCF (mm) 14 (11–17) 12 (8–18) 9 (6–12) 11 (8–13)
Multiplate-ADP(AUC) 77 (51–89) 69 (58–101) 66 (53–79) 80 (53–102)
Multiplate-TRAP(AUC) 135 (120–171) 139 (123–169) 140 (128–152) 158 (128–177)
Table 3 The p values when comparing ROTEM and Multiplate parameters of brain tumour neurosurgery patients after colloid
infusions before surgery. Results after each colloid infusion (250 ml for HA and 500 ml for HES) as well as at the end of surgery were
compared to pre-operative results using Wilcoxon’s signed ranked test
CT (s) CFT (s) AA (°) EXTEM-MCF (mm) FIBTEM-MCF (mm) Multiplate ADP(AUC) Multiplate TRAP(AUC)
HA 250 ml ns ns ns ns 0.0015 (**) ns ns
HA 500 ml ns 0.0098 (**) 0.0156 (*) 0.0039 (**) 0.0039 (**) 0.0020 (*) ns
HA end of surgery ns 0.0011 (**) 0.0012 (**) 0.0098 (**) 0.0042 (**) ns ns
HES 500 ml ns <0.0001 (****) 0.0001 (***) 0.0005 (***) ns ns ns
HES 1000 ml 0.0156 (*) 0.0020 (**) 0.0039 (**) ns 0.0020 (**) ns ns
HES end of surgery ns 0.0027 (**) 0.0015 (**) ns 0.0043 (**) ns ns
Significance level was set at p < 0.017, **p < 0.01, ***p < 0.001 and ****p < 0.0001
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HES test group but almost none in the HA group. As
seen in Fig. 1 and Table 2, CFT increased, and AA de-
creased with successive colloid infusions, which probably
reflects a dilution effect on coagulation factors.
The difference in CFT and AA between test groups
could be due to the different volumes of colloids given.
Patients receiving HA were given an infusion of 500 ml
in total, while those receiving HES had >double the vol-
ume, thus probably leading to a greater extent of initial
dilution. Haemodilution could also explain why the CT
parameter only changed after 1000 ml HES. The efficacy
of volume replacement therapy depends on the initial
plasma volume-expanding effect of the colloid and the
duration of its effect. At the start of the present study,
when HES data were collected, all patients received
consecutive doses of 500 ml HES intra-operatively.
However, with the new 5 % HA fluid regimen at our
centre, very few patients received more than 500 ml
for haemodynamic stabilisation and initial blood-loss
replacement, probably due to a greater and enduring
volume-expanding effect of HA as compared to HES
(Dubniks et al. 2009). However, the fluid therapy used
in this study is only empiric-based. Future studies
should involve blood/plasma volume measurements or
cardiac output measurements to better evaluate the
colloid insult on haemostasis.
MCF measures the amplification and propagation of
the clot, dependent on fibrin polymerisation and platelet
function. EXTEM- and FIBTEM-MCF are the most
widely used parameters in clinical settings for assessing
coagulation since they correlate strongly with traditional
tests, most notably plasma fibrinogen (Theusinger et al.
2013; Haas et al. 2012). In our study, EXTEM-MCF de-
creased after the second volume infusion of HA, but
already after the first volume of HES.
With FIBTEM-MCF, we observe a similar decrease,
although it was now present after the first volume of
HA. This is in accordance with previous studies, since
colloids are known to affect coagulation through dilu-
tion as well as interaction with coagulation factors
and fibrin polymerisation. HES has been especially
well-documented to exert its effects on coagulation
Fig. 1 ROTEM CT and CFT values of patients undergoing elective brain tumour neurosurgery. Blood samples were taken before the start of
surgery, after receiving colloid infusions (human albumin (HA) or hydroxyethyl starch (HES) 130/0.4 and at the end of surgery. Boxplots showing
median and interquartile range with min-max whiskers and + signs identifying mean values
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by interacting with FXIII and fibrin polymerisation
(Nielsen 2005). Fenger-Eriksen et al. showed that HES
decreases coagulation factors (e.g. fibrinogen, FII, FX,
FXIII) more than can be expected from haemodilu-
tion alone, suggesting that the resulting coagulopathy
could be due to an acquired fibrinogen deficiency
(Fenger-Eriksen et al. 2009).
The specific effects of HA on coagulation in vivo are
not as well documented. Some studies imply that HA af-
fects coagulation by decreasing platelet aggregation
(Jorgensen & Stoffersen 1980; Kim et al. 1999). Another
study showed that HA infusions are linked to decreased
fibrinogen levels (Johnson et al. 1979); although, it is un-
clear whether this is merely an effect of haemodilution.
Niemi et al. observed a hypercoagulative effect of HA
haemodilution (Niemi & Kuitunen 1998), but this effect
could not be reproduced in clinical settings (Niemi et al.
2005). In our study, the difference in volume required
for MCF to be affected by each colloid might be
accounted for by the different biochemical properties of
HES and HA. In clinical bleeding situations, FIBTEM-
MCF of <10 mm can indicate plasma fibrinogen defi-
ciency and prompts the use of fibrinogen concentrate or
fresh-frozen plasma (Bolliger et al. 2012). The minimum
values were especially low in the HES group where it
registered as low as 4 mm.
However, we found no correlation between lower
FIBTEM-MCF values and increased perioperative bleed-
ing in our data, as blood losses were similar in both test
groups.
For inter-group comparisons, several parameters
differed between the test groups after the first colloid
infusion. However, after the second infusion, no fur-
ther changes could be seen. Furthermore, CT and
FIBTEM-MCF both differed between groups at the end of
surgery. The difference in CT was already present pre-
operatively, but the change in FIBTEM-MCF is possibly
due to the more prominent effects of HES on clot stability;
as discussed earlier, HES is known to weaken clot
structure (Mittermayr et al. 2007). Previous studies
Fig. 2 ROTEM EXTEM-MCF and FIBTEM-MCF values of patients undergoing elective brain tumour neurosurgery. Blood samples were taken before
the start of surgery, after receiving colloid infusions (human albumin (HA) or hydroxyethyl starch (HES) 130/0.4 and at the end of surgery. Boxplots
showing median and interquartile range with min-max whiskers and + signs identifying mean values
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have found hypercoagulative ROTEM tracings at lower
haemoglobin levels (Nagler et al. 2013; Solomon et al.
2013), but no such effect could be observed with certainty
in our study.
At Lund University Hospital, 5 % HA is the pre-
ferred colloid for neurosurgery right now due to its
ability to maintain plasma oncotic pressure. With a
20 % HA alleviation of cerebral oedema is possible
(Jungner et al. 2010). However, it is hard to foresee
changes in blood brain barrier that might contribute
to oedema during elective brain tumour resection, so
control of oncotic pressure with albumin for these
types of patients is controversial.
In neurosurgery, haemostatic control poses a sig-
nificant problem, as the balance between coagulation
and bleeding must be maintained. If HA is to be
preferred over HES, there might be a limitation to
the appropriate volume of HA infusion. Either from
haemodilution or another mechanism, HA seems to
have an impact on coagulation. At Lund University
Hospital, the upper limit of HA infusions is usually
500 ml for neurosurgical patients, with only a few
receiving 750 ml. With regard to our data, infusions
of these volumes might require monitoring with
ROTEM or laboratory-based methods in order to detect
coagulopathy and the need for fibrinogen or other
transfusions. HA might be preferable in this regard
since HA-induced coagulopathy is more easily re-
versed with fibrinogen concentrate than coagulopathy
induced by HES, at least in vitro (Winstedt et al. 2013;
Schlimp et al. 2013).
There are several limitations to this study. This study
is not double-blinded or randomised. Initially, the aim
was to study the safety of HES, as HES was our routine
Fig. 3 Multiplate ADP and TRAP AUC values of patients undergoing elective brain tumour neurosurgery. Blood samples were taken before the
start of surgery, after receiving colloid infusions (human albumin (HA) or hydroxyethyl starch (HES) 130/0.4 and at the end of surgery. Boxplots
showing median and interquartile range with min-max whiskers and + signs identifying mean values
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for haemodynamic stabilisation and initial blood-loss re-
placement in elective neurosurgery. This routine was
later replaced by HA. It is underpowered to detect a cor-
relation between our findings and clinical bleeding/post-
operative complications. In ROTEM/Multiplate systems,
results might not always correlate with clinical bleeding
as there is no blood flow or endothelial interactions that
affect coagulation in vivo.
We did not use the same amount of HA and HES.
The patients received a mean of 375 ml HA but a mean
of 861 ml HES, which is 230 % more fluid. From our
very basic haemodynamic monitoring, there was an im-
pression that the need for HA volume was much less
than that of the HES volume. However, to measure this
in an optimal way, we should have used blood-volume
measurements or at least cardiac output monitoring.
The volumes of HA and HES were not controlled by
us, but by the anaesthetist in charge, trying to opti-
mise MAP, systolic blood pressure, systolic blood
pressure and PPV on top of replacing initial blood
loss with 1–2 ml of the respective colloid for every
millilitre of blood loss.
Dubnics M et al. have published two works on HES
versus Albumin [Dubnics et al. 2007; Dubnics et al.
2009]. In short, one can say that they showed that 3 h
after rescucitation with HES and HA (20 ml/kg) after
bleeding in guinea pigs, plasma volume (PV) increased
by 27 ml/kg in the HA group and 18 ml/kg in the HES
group, equal to 1.5 times more HES needed to get the
same PV-expanding effect. Corresponding PV expansion
in a rat with increased permeability was 17 mL/kg for
HA and 7 ml/kg of HES equal to 2.4 times as much
HES albumin that needs to be given for the same PV ex-
pansion. Since the surgery, and bleeding is not likely to
give the same greater permeability increase, it is more
probable that the ratio for the conditions prevailing at
neurosurgery are closer to 1.5 than 2.4, maybe 2.
The Saline protocol used by department may not
be optimal, although we did not find any signs of
hyperchloremic acidosis, hypernatremia or renal fail-
ure in our patients. Balanced crystalloids may be
better [van Haren et al. 2014] from these aspects.
Also, balanced crystalloids may be better than saline
(and albumin) to maintain coagulation (Smith et al.
2015; Pathirana et al. 2015).
Finally, as this is a pilot study carried out during a
limited period of time, the sample sizes are small,
and conclusions must therefore be drawn with care
regarding the preference of HA over HES as a
neurosurgical fluid therapy. Nevertheless, as this
study investigates clinically used fluid-therapy rou-
tines as opposed to fluid regimes designed a priori,
the results are easier to apply to real-life clinical
settings.
Conclusions
There were no clinically relevant differences concerning
kidney function, bleeding or coagulation; although,
ROTEM and Multiplate measurements indicated both
inter- and intra-group statistical differences. Albumin
had a certain impact on coagulation; especially after
500 ml infusion, the ROTEM changes are close to those
induced by 1000 ml hydroxyethyl starch. Clot structure
measured by ROTEM FIBTEM-MCF was significantly
lower with HES at the end of surgery, but HES had been
infused at higher volumes to maintain intra-operative
haemodynamics. Unlike previous studies that focused on
thromboelastography, we also used Multiplate to assess
coagulation, but no significant changes could be de-
tected other than after 500 ml HA infusion, and those
changes were normalised by the end of surgery. HA
seems to be a more favourable fluid for volume replace-
ment in neurosurgical patients at restricted volumes of
infusion; however, larger studies need to be carried out
for more conclusive results and preferably with plasma
volume measurements. Irrespective of the type of fluid
regimen, intra-operative monitoring of coagulation dur-
ing neurosurgery is recommended.
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